Page last updated: 2024-12-06

fosinoprilat

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

fosinoprilat: active phosphinic acid metabolite of prodrug fosenopril, which is activated by esterases in vivo; structure given in first source; binds zinc with phosphinic acid group [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

fosinoprilat : A phosphinic acid-containing N-acyl derivative of (4S)-cyclohexyl-L-proline. An inhibitor of angiotensin converting enzyme (ACE), it is used as the phosphinate ester pro-drug fosinopril for treatment of hypertension and chronic heart failure. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID62956
CHEMBL ID581
CHEBI ID116962
SCHEMBL ID124537
MeSH IDM0135833

Synonyms (60)

Synonym
fosinoprilat (usan/inn)
D03772
95399-71-6
sq 27,519
fosinoprilat
sq-27,519
sq-27519
fosfenopril
fosinopril diacid
fosinoprilat [usan:inn]
l-proline, 4-cyclohexyl-1-((hydroxy(4-phenylbutyl)phosphinyl)acetyl)-, trans-
fosinoprilatum [inn-latin]
(4s)-4-cyclohexyl-1-((hydroxy(4-phenylbutyl)phosphinyl)acetyl)-l-proline
fosinoprilic acid
CHEBI:116962 ,
(4s)-4-cyclohexyl-1-{[hydroxy(4-phenylbutyl)phosphoryl]acetyl}-l-proline
4-cyclohexyl-1-{2-[hydroxy-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid
(2s,4s)-4-cyclohexyl-1-{2-[hydroxy-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid
fosinoprilatum
(2s,4s)-4-cyclohexyl-1-{2-[hydroxy(4-phenylbutyl)phosphoryl]acetyl}pyrrolidine-2-carboxylic acid
(2s,4s)-4-cyclohexyl-1-[2-[hydroxy(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid
CHEMBL581 ,
so-27519
so 27,519
pu6ba2d2md
bdbm50018849
s312ey6zt8 ,
unii-s312ey6zt8
gtpl6457
(2s,4s)-4-cyclohexyl-1-[2-(hydroxy-(4-phenylbutyl)phosphoryl)acetyl]pyrrolidine-2-carboxylic acid
fosinoprilat [inn]
(2s,4s)-4-cyclohexyl-1-((hydroxy(4-phenylbutyl)phosphoryl)acetyl)pyrrolidine-2-carboxylic acid
fosinoprilat [usan]
fosinopril sodium impurity a [ep impurity]
fosinopril diacid [mi]
SCHEMBL124537
C21542
fosinopril impurity a
WOIWWYDXDVSWAZ-RTWAWAEBSA-N
1[{hydroxy(4-phenylbutyl)phosphinyl}acetyl]-(trans)-4-cyclohexyl-l-proline
HY-107352
(4s)-4-cyclohexyl-[(4-phenylbutyl)phosphinyl]acetyl-l-proline
(2s,4s)-4-cyclohexyl-1-(2-(hydroxy(4-phenylbutyl)phosphoryl)acetyl)pyrrolidine-2-carboxylic acid
ks8 ,
AKOS032953851
DTXSID80869253 ,
forsinoprilat
DB14207
Q27077720
trans-4-cyclohexyl-1-[[hydroxy(4-phenylbutyl)phosphinyl]acetyl]-l-proline
l-proline, 4-cyclohexyl-1-[[hydroxy(4-phenylbutyl)phosphinyl]acetyl]-,(4s)-
sq27,519
CS-0028200
fosinoprilatum (inn-latin)
dtxcid60820726
(2s,4s)-4-cyclohexyl-1-(2-(hydroxy-(4-phenyl-butyl)-phosphinoyl)-acetyl)-pyrrolidine-2-carboxylic acid
4-cyclohexyl-1-(2-(hydroxy-(4-phenyl-butyl)-phosphinoyl)-acetyl)-pyrrolidine-2-carboxylic acid
(4s)-4-cyclohexyl-1-((hydroxy(4-phenylbutyl)phosphoryl)acetyl)-l-proline
fosinopril sodium impurity a (ep impurity)
l-proline,4-cyclohexyl-1-[2-[hydroxy(4-phenylbutyl)phosphinyl]acetyl]-,(4s)-

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" These data show that fosinopril is a safe and effective inhibitor of ACE with a long duration of action on serum ACE activity."( Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects.
Duchin, KL; Frantz, M; Manning, J; Tu, JI; Waclawski, AP; Willard, DA, 1991
)
0.28

Pharmacokinetics

The oral half- life of fosinoprilat was significantly longer than the intravenous half-life for both the patients with CHF and normal subjects. Serum aldosterone levels, ACE activity, and sitting blood pressure were determined.

ExcerptReferenceRelevance
" Serum aldosterone levels, ACE activity, and sitting blood pressure were determined, as were pharmacokinetic parameters of fosinoprilat, the active diacid of fosinopril."( Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects.
Duchin, KL; Frantz, M; Manning, J; Tu, JI; Waclawski, AP; Willard, DA, 1991
)
0.49
" No statistically significant differences were detected in fosinoprilat pharmacokinetic values between healthy and hepatically impaired subjects."( Single-dose and steady-state pharmacokinetics of fosinopril and fosinoprilat in patients with hepatic impairment.
Ford, NF; Hammett, JL; Lasseter, KC; Manning, J; Raymond, R; Van Harken, DR, 1995
)
0.77
" Pharmacokinetic variables of the patients were similar to those in patients with moderate to severe renal dysfunction."( The pharmacokinetics and pharmacodynamics of fosinopril in haemodialysis patients.
Duchin, KL; Gehr, TW; Grasela, DM; Sica, DA, 1993
)
0.29
" The oral half-life of fosinoprilat was significantly longer than the intravenous half-life for both the patients with CHF and normal subjects, without statistically significant differences between the study groups."( Fosinopril: pharmacokinetics and pharmacodynamics in congestive heart failure.
Delaney, C; Garland, WT; Kostis, JB; Liao, WC; Norton, J, 1995
)
0.6
" Pharmacokinetic parameters were calculated by fitting the plasma or serum concentrations to a three-compartment model."( Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration.
Chu, KM; Ding, PY; Hu, OY; Huang, CS; Hwang, GM, 1997
)
0.62
" Samples of blood were collected for determination of pharmacokinetic parameters."( Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency.
Caspi, A; Greenbaum, R; Liao, WC; Mangold, B; Nouriel, H; O'Grady, P; Paz, R; Sclarovsky, S; Yee, KF; Zucchelli, P, 2000
)
0.58
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Bioavailability

ExcerptReferenceRelevance
" The RIA has been used routinely in support of the bioavailability and pharmacokinetic studies of fosinopril in humans."( A radioimmunoassay for SQ 27,519, the active phosphinic acid-carboxylic diacid of the prodrug fosinopril in human serum.
Brennan, J; Eckelman, WC; Stouffer, B; Tu, JI, 1990
)
0.28
" Drug disposition studies in rats, dogs, and monkeys have demonstrated that the method can be readily adapted to any ACE inhibitor and is suitable for determining drug bioavailability and pharmacokinetics."( Radioenzymatic assay of angiotensin-converting enzyme inhibitors in plasma and urine.
Alpaugh, WC; Stauber, KL; Swanson, BN; Weinstein, SH, 1985
)
0.27
" Following oral administration of 14C-fosinopril, mean Cmax, time to maximum plasma concentration (tmax), and fosinoprilat bioavailability values were 197 ng."( The pharmacokinetics and pharmacodynamics of fosinopril in haemodialysis patients.
Duchin, KL; Gehr, TW; Grasela, DM; Sica, DA, 1993
)
0.5
" Absolute bioavailability was approximately 29%."( Fosinopril: pharmacokinetics and pharmacodynamics in congestive heart failure.
Delaney, C; Garland, WT; Kostis, JB; Liao, WC; Norton, J, 1995
)
0.29

Dosage Studied

Chinese may require a lower fosinoprilat dosage to obtain plasma concentrations similar to whites after intravenous administration.

ExcerptRelevanceReference
" Fosinopril was administered at a dosage of 10 mg once daily for 14 days."( Single-dose and steady-state pharmacokinetics of fosinopril and fosinoprilat in patients with hepatic impairment.
Ford, NF; Hammett, JL; Lasseter, KC; Manning, J; Raymond, R; Van Harken, DR, 1995
)
0.53
" Dosage modifications or supplemental dosing following dialysis are unnecessary."( The pharmacokinetics and pharmacodynamics of fosinopril in haemodialysis patients.
Duchin, KL; Gehr, TW; Grasela, DM; Sica, DA, 1993
)
0.29
" Chinese may require a lower fosinoprilat dosage to obtain plasma concentrations similar to whites after intravenous administration."( Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration.
Chu, KM; Ding, PY; Hu, OY; Huang, CS; Hwang, GM, 1997
)
0.91
"To compare the serum pharmacokinetics of fosinoprilat with enalaprilat and lisinopril after 1 and 10 days of dosing with fosinopril, enalapril and lisinopril."( Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency.
Caspi, A; Greenbaum, R; Liao, WC; Mangold, B; Nouriel, H; O'Grady, P; Paz, R; Sclarovsky, S; Yee, KF; Zucchelli, P, 2000
)
0.84
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitorAn EC 3.4.15.* (peptidyl-dipeptidase) inhibitor that interferes with the action of peptidyl-dipeptidase A (EC 3.4.15.1).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
phosphinic acids
L-proline derivativeA proteinogenic amino acid derivative resulting from reaction of L-proline at the amino group or the carboxy group, or from the replacement of any hydrogen of L-proline by a heteroatom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Fosinopril Action Pathway34
Fosinopril Metabolism Pathway12

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Angiotensin-converting enzyme Homo sapiens (human)Ki0.00150.00000.82557.5000AID689997
Angiotensin-converting enzymeOryctolagus cuniculus (rabbit)Ki0.00150.00042.03378.6606AID37801
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Angiotensin-converting enzymeRattus norvegicus (Norway rat)T500.01100.01100.01100.0110AID38273
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (56)

Processvia Protein(s)Taxonomy
response to hypoxiaAngiotensin-converting enzyme Homo sapiens (human)
kidney developmentAngiotensin-converting enzyme Homo sapiens (human)
blood vessel remodelingAngiotensin-converting enzyme Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme Homo sapiens (human)
regulation of renal output by angiotensinAngiotensin-converting enzyme Homo sapiens (human)
neutrophil mediated immunityAngiotensin-converting enzyme Homo sapiens (human)
antigen processing and presentation of peptide antigen via MHC class IAngiotensin-converting enzyme Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme Homo sapiens (human)
proteolysisAngiotensin-converting enzyme Homo sapiens (human)
spermatogenesisAngiotensin-converting enzyme Homo sapiens (human)
female pregnancyAngiotensin-converting enzyme Homo sapiens (human)
regulation of blood pressureAngiotensin-converting enzyme Homo sapiens (human)
male gonad developmentAngiotensin-converting enzyme Homo sapiens (human)
response to xenobiotic stimulusAngiotensin-converting enzyme Homo sapiens (human)
embryo development ending in birth or egg hatchingAngiotensin-converting enzyme Homo sapiens (human)
post-transcriptional regulation of gene expressionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of gene expressionAngiotensin-converting enzyme Homo sapiens (human)
substance P catabolic processAngiotensin-converting enzyme Homo sapiens (human)
bradykinin catabolic processAngiotensin-converting enzyme Homo sapiens (human)
regulation of smooth muscle cell migrationAngiotensin-converting enzyme Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
animal organ regenerationAngiotensin-converting enzyme Homo sapiens (human)
response to nutrient levelsAngiotensin-converting enzyme Homo sapiens (human)
response to lipopolysaccharideAngiotensin-converting enzyme Homo sapiens (human)
mononuclear cell proliferationAngiotensin-converting enzyme Homo sapiens (human)
response to laminar fluid shear stressAngiotensin-converting enzyme Homo sapiens (human)
angiotensin-activated signaling pathwayAngiotensin-converting enzyme Homo sapiens (human)
vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
hormone metabolic processAngiotensin-converting enzyme Homo sapiens (human)
hormone catabolic processAngiotensin-converting enzyme Homo sapiens (human)
eating behaviorAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of apoptotic processAngiotensin-converting enzyme Homo sapiens (human)
peptide catabolic processAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of glucose importAngiotensin-converting enzyme Homo sapiens (human)
regulation of synaptic plasticityAngiotensin-converting enzyme Homo sapiens (human)
lung alveolus developmentAngiotensin-converting enzyme Homo sapiens (human)
amyloid-beta metabolic processAngiotensin-converting enzyme Homo sapiens (human)
arachidonic acid secretionAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of neurogenesisAngiotensin-converting enzyme Homo sapiens (human)
heart contractionAngiotensin-converting enzyme Homo sapiens (human)
regulation of angiotensin metabolic processAngiotensin-converting enzyme Homo sapiens (human)
hematopoietic stem cell differentiationAngiotensin-converting enzyme Homo sapiens (human)
angiogenesis involved in coronary vascular morphogenesisAngiotensin-converting enzyme Homo sapiens (human)
cellular response to glucose stimulusAngiotensin-converting enzyme Homo sapiens (human)
response to dexamethasoneAngiotensin-converting enzyme Homo sapiens (human)
cell proliferation in bone marrowAngiotensin-converting enzyme Homo sapiens (human)
regulation of heart rate by cardiac conductionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of calcium ion importAngiotensin-converting enzyme Homo sapiens (human)
response to thyroid hormoneAngiotensin-converting enzyme Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme Homo sapiens (human)
regulation of hematopoietic stem cell proliferationAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of gap junction assemblyAngiotensin-converting enzyme Homo sapiens (human)
cellular response to aldosteroneAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of peptidyl-cysteine S-nitrosylationAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of systemic arterial blood pressureAngiotensin-converting enzyme Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
endopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
metalloendopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
calmodulin bindingAngiotensin-converting enzyme Homo sapiens (human)
peptidase activityAngiotensin-converting enzyme Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
exopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
tripeptidyl-peptidase activityAngiotensin-converting enzyme Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme Homo sapiens (human)
chloride ion bindingAngiotensin-converting enzyme Homo sapiens (human)
mitogen-activated protein kinase kinase bindingAngiotensin-converting enzyme Homo sapiens (human)
bradykinin receptor bindingAngiotensin-converting enzyme Homo sapiens (human)
mitogen-activated protein kinase bindingAngiotensin-converting enzyme Homo sapiens (human)
metallodipeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
heterocyclic compound bindingAngiotensin-converting enzyme Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
extracellular spaceAngiotensin-converting enzyme Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme Homo sapiens (human)
lysosomeAngiotensin-converting enzyme Homo sapiens (human)
endosomeAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
external side of plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
basal plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme Homo sapiens (human)
sperm midpieceAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID182322% Inhibition of angiotensin-I induced pressor response in normotensive rats after intravenous dosing of 0.5 umol/kg1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines.
AID689997Inhibition of ACE2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Remarkable potential of the α-aminophosphonate/phosphinate structural motif in medicinal chemistry.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID182320% Inhibition of angiotensin-I induced pressor response in normotensive rats after intravenous dosing of 0.05 umol/kg1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID689956Terminal half life in healthy human at 10 mg dosed as single daily dose2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Remarkable potential of the α-aminophosphonate/phosphinate structural motif in medicinal chemistry.
AID197409% Inhibition of angiotensin-I induced pressor response in normotensive rats after peroral dosing of 15 umol/kg1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID37801Inhibitory activity against rabbit lung angiotensin-1 converting enzyme1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines.
AID182330% Inhibition of angiotensin-I induced pressor response in normotensive rats after peroral dosing of 5 umol/kg1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines.
AID182321% Inhibition of angiotensin-I induced pressor response in normotensive rats after intravenous dosing of 0.15 umol/kg1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID689957Total body clearance in healthy human at 10 mg dosed as single daily dose2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Remarkable potential of the α-aminophosphonate/phosphinate structural motif in medicinal chemistry.
AID38273In vitro inhibition of rat Angiotensin I converting enzyme1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (16.13)18.7374
1990's12 (38.71)18.2507
2000's8 (25.81)29.6817
2010's4 (12.90)24.3611
2020's2 (6.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.50 (24.57)
Research Supply Index3.64 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (12.12%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (87.88%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]